Printer Friendly

Interlaboratory evaluation of rodent pulmonary responses to engineered nanomaterials: the NIEHS Nano GO Consortium.

Rapid development of the nanotechnology industry is resulting in the production of a variety of engineered nanomaterials (ENMs) for structural support, electronics, energy, medical imaging, and drug delivery, as well as other applications. Although nano-technology offers enormous potential societal benefits, concerns have been raised about the safety of ENM-containing products in regard to human and environmental health. Cumulative evidence suggests that some ENMs may exert adverse effects on the lung and other organ systems (Xia et al. 2009). These potential risks must be addressed in order to develop safe nanotechnology, but setting and implementing exposure standards require predictable results proven reliable by repeatability and agreement among multiple investigators. Because of the lack of standard protocols and reagents, ENM toxicity studies are difficult to compare because of inconsistencies in health outcomes and/ or toxic thresholds. Much of this discordance can be attributed to a) heterogeneity of ENMs from batch to batch; b) inherent difficulties of interlaboratory comparisons; c) agglomeration of particles, which often changes toxicity; d) method and duration of dosing and dose level; and e) method of ENM manipulation prior to testing.

In addition to dose, many factors influence the toxicity of ENMs, including surface characteristics, charge, and shape. Size alone is a major determinant because many bulk materials that are relatively inert become toxic when produced at the nanoscale (Borm et al. 2006; Nel et al. 2006). Commonly produced and high production volume ENMs are carbon-based (e.g., nanotubes, graphene, fullerenes), metal-based [e.g., gold, silver, quantum dots, titanium dioxide (Ti[O.sub.2]), zinc oxide], or of a biologic nature (e.g., liposomes and viruses designed for gene or drug delivery) (Card et al. 2008). Which ENMs will present the greatest potential threat to human health depends on relative toxicity and on the potential for exposure. Ti[O.sub.2] is one of the most widely used nanoscale materials to date, and the conversion of bulk to nanoscale Ti[O.sub.2] in consumer products (e.g., sunscreens) and industrial products (e.g., paints) is rapidly increasing (Robichaud et al. 2009). From a human health standpoint, this is significant because bulk Ti[O.sub.2] nanoparticles demonstrate increased toxicity compared with larger Ti[O.sub.2] particles (Oberdorster et al. 2005). Moreover, Ti[O.sub.2] nanoparticles can be manipulated into wire and belt shapes. The production of multiwalled carbon nanotubes (MWCNTs) is also increasing rapidly, along with a diversity of manipulations to alter physical and chemical attributes for various applications in industry, electronics, and medicine. Several studies have already shown that some types of MWCNTs delivered to the lungs by inhalation, intratracheal instillation (IT), or oropharyngeal aspiration (OPA) cause inflammation and fibrosis (Bonner 2010).

The goal of the Nano GO Consortium, an interlaboratory, multiinvestigator project, was to determine whether independent investigators involved in National Institute of Environmental Health Sciences (NIEHS)-funded consortium studies could generate consistent data sets in rodents using a well-characterized and commonly sourced panel of ENMs (Xia et al. 2013) and harmonized protocols for nanoparticle dispersion, delivery to the lungs, and collection of tissues. ENMs tested by this consortium included Ti[O.sub.2] anatase/rutile nanospheres (Ti[O.sub.2]-P25), 100% anatase spheres (Ti[O.sub.2]-A), and anatase nanobelts (Ti[O.sub.2]-NBs), as well as three different MWCNTs, including the original material (O-MWCNT), a purified form with partial metal removal (P-MWCNT), and a carboxylic acid-functionalized form (F-MWCNT). Four laboratories evaluated lung responses in C57BL/6 mice exposed to ENMs by OPA exposure, and three labs tested responses in Sprague-Dawley (SD) or Fischer 344 (F344) rats following IT exposure. The results presented here demonstrate that a standard protocol can be used across multiple labs to yield similar results in the pulmonary inflammatory response. We also make recommendations for future directions in testing ENMs in a harmonized fashion among multiple labs. These recommendations should serve to guide regulatory agencies in making decisions regarding standard setting for occupational and environmental exposures to ENMs that present potential risks to human health and the environment.

Materials and Methods

ENMs. The physical and chemical characteristics of nanoparticles used in this study are described in detail by Xia et al. (2013). We used three different formulations of Ti[O.sub.2] nanoparticles: Ti[O.sub.2]-P25, Ti[O.sub.2]-A, and Ti[O.sub.2]-NBs. We obtained the Ti[O.sub.2]-A from P. Biswas (Department of Energy, Environmental & Chemical Engineering, Washington University, St. Louis, MO); Ti[O.sub.2]-P25 nanoparticles from Evonik (Essen, Germany); Ti[O.sub.2]-NBs from N. Wu (Mechanical and Aerospace Engineering, West Virginia University, Morgantown, WV); MWCNTs from S. Mitra (Department of Chemistry and Environmental Science, New Jersey Institute of Technology, Newark, NJ); O-MWCNT from CheapTubes, Inc. (Brattleboro, VT). Two modified forms of O-MWCNTs were tested: P-MWCNT was derived from O-MWCNT by acid purification to remove residual metal catalyst, and F-MWCNT was derived from O-MWCNT by the addition of -COOH groups via carboxylic acid treatment to the nanotube surface.

Preparation of ENM suspensions. ENMs were suspended in dispersion medium (DM) containing disaturated phosphatidylcholine in 100% ethanol (DSPC; Sigma-Aldrich, St. Louis, MO); rat, mouse, or bovine serum albumin (Sigma-Aldrich); and 0.9% sterile saline (Porter et al. 2008). Spherical Ti[O.sub.2] nanoparticle and MWCNT suspensions were dispersed using a cup-horn sonicator (three mouse labs) for 1 min or a probe sonicator (rat labs and one mouse lab) for 30 min using a 10-sec on/off duty cycle and ice bath to disperse the particles and ensure that the sample temperature did not exceed 28[degrees]C. Ti[O.sub.2]-NBs were not sonicated because preliminary studies showed that this causes axial fractures. Instead, Ti[O.sub.2]-NBs were suspended in DM using gentle mechanical stirring for 60 min at room temperature. Control animals received DM alone that had been sonicated/stirred as described above.

Consortium labs. Four labs evaluated the lung responses of C57BL/6 mice exposed to ENMs by OPA exposure, and three labs tested responses in SD or F344 rats using IT exposure. There were four mouse lab groups: North Carolina State University (ML1), East Carolina University (ML2), Michigan State University (ML3), and University of Washington (ML4). There were three rat lab groups: National Institute for Occupational Safety and Health (RL1; SD rats), University of California, Davis (RL2; SD rats), and University of Rochester (RL3; F344 and SD rats). Lab codes were randomly assigned, and no identification is implied here. The first round of in vivo studies involved three independent labs, all of which used SD rats that were exposed to either Ti[O.sub.2]-P25 or Ti[O.sub.2]-A in DM. None of the treatment groups reported statistically significant changes in lung inflammatory parameters relative to DM controls; therefore, the scope of the consortium studies was expanded to include another rat strain (F344) and another species (mouse, C57BL6). The goal of this expansion was to strengthen conclusions about the relative toxicity of the selected ENMs that were evaluated.

Experimental design. ENMs (10, 20, or 40 [micro]g in 50 [micro]L DM) were delivered to the lungs of 6- to 8-week-old male C57BL/6 mice (20-25 g body weight) via OPA. Ti[O.sub.2] particles (20, 70, or 200 [micro]g in 250 [micro]L DM) or MWCNTs (10, 50, or 200 [micro]g in 250 [micro]L DM) were delivered to the lungs of 8- to 10-week-old male SD and F344 rats (350-420 g body weight) via IT. Lung tissues and bronchoalveolar lavage fluid (BALF) were collected at 1 and 7 days after exposure to Ti[O.sub.2] nanoparticles and 1 and 21 days after exposure to MWCNTs. BALF samples (three per mouse and five per rat) for each animal were combined and evaluated for total and differential cell counts [macrophages, neutrophils, eosinophils, and lymphocytes] and for measurement of total protein concentration and lactate dehydrogenase (LDH) activity. Total cell numbers were determined by counting the cells on three nonoverlapping images taken at 20x magnification, and the percentage of cell type per total cell population was determined by counting 500 cells per sample. For histopathological analysis, tissue sections from the left lung lobe were stained with hematoxylin and eosin (H&E). Immunohistochemistry was performed on tissue sections using a monoclonal rat anti-mouse neutrophil (allotypic marker clone 7/4) antibody (AbD Serotec, Raleigh, NC). Additional details are provided in Supplemental Material, Supplemental Methods and Materials, pp. 3-4 (http:// We present values as the percentage of neutrophils because it is not possible to compare effects of ENMs across labs or species using absolute neutrophil numbers as a result of variability related to lung size and lavage technique. All animals were treated humanely and with regard for alleviation of suffering.

Statistical analysis. Data are presented as mean [+ or -] SE for groups of four to six mice or rats. We performed two-way analyses of variance (ANOVA) and post hoc Tukey's test or post hoc Bonferroni t-test. The analyses considered the main effects of and interactions between the factors, dose, and lab. In many cases, the two-way interaction was not statistically significant, so independent one-way analyses were performed. We considered p [less than or equal to] 0.05 to be statistically significant. Statistical analyses were performed using Graphpad Prism 5 (Graphpad Software, LaJolla, CA) and SigmaPlot 11 (Systat Software Inc., San Jose, CA).


Mice. Ti[O.sub.2]. Differential counting of cells retrieved in BALF showed that all Ti[O.sub.2] ENMs tested increased the percentage of neutrophils relative to other cell types (macrophages, lymphocytes, and eosinophils). Results are shown only for the highest dose (40 [micro]g/50 [micro]L) because no significant effect on lung inflammation was observed at the lower doses. At 1 day postexposure, the relative percentage of neutrophils was significantly increased by Ti[O.sub.2]-P25 in two of four labs (Figure 1A), by Ti[O.sub.2]-A in one of four labs (Figure 1B), and by Ti[O.sub.2]-NB in three of four labs (Figure 1C). By day 7 postexposure, neutrophilic inflammation in all Ti[O.sub.2] treatment groups returned to nearly baseline levels. Macrophages comprised > 95% of total BALF cells retrieved from the lungs of control mice (exposed to DM alone) (data not shown). Ti[O.sub.2] nanoparticles did not cause significant increases in the relative percentages of lymphocytes or eosinophils, except for a slight increase in the relative percentage of eosinophils observed by one lab after treatment with Ti[O.sub.2]-NB (data not shown). BALF cytospins confirmed that inflammation caused by nanoparticle exposure was due primarily to neutrophil influx (data not shown). All four mouse labs observed that Ti[O.sub.2]-NB caused an inflammatory response at the terminal bronchiol ar region and the alveolar duct bifurcation region of the distal lung in mice 1 day after OPA delivery (Figure 2). Ti[O.sub.2]-NBs were easily detectable by polarized light microscopy and were localized primarily in alveolar macrophages.

MWCNTs. Differential cell counts showed that the percentages of neutrophils were increased relative to other cell types in mouse BALF at 1 day postexposure to all forms of MWCNTs (O-MWCNT, P-MWCNT, and F-MWCNT) at 40 [micro]g/50 [micro]L (Figure 3). Lower doses of MWCNTs caused no significant effects on neutrophilia. In mice treated with MWCNTs, no significant increases were observed in the relative percentages of lymphocytes or eosinophils (data not shown). Light microscopic images of BAL cytospins confirmed that changes in the relative percentage of BAL cells were due to a significant increase in neutrophils produced by treatment with MWCNTs (data not shown). O-MWCNTs caused the greatest increases in neutrophils at 1 day postexposure in three of four labs compared with P-MWCNTs and F-MWCNTs (Figure 3). The inflammatory responses to all MWCNTs subsided to control levels by 21 days postexposure (data not shown). Combining the data from the four labs demonstrated the following order of potency: O-MWCNTs > P-MWCNTs > F-MWCNTs, albeit not to a significant extent [see Supplemental Material, Figure S1 (]. However, combining the data from three of the four labs (ML1, ML2, and ML3) that initially showed significant effects of MWCNTs on neutrophils demonstrated a significant difference between O-MWCNTs and F-MWCNTs (see Supplemental Material, Figure S1). All four labs demonstrated that total protein and LDH levels in BALF were increased by all forms of MWCNTs or Ti[O.sub.2] nanoparticles, although these two end points of lung injury were highly variable among labs (data not shown).


Histopathological analysis was used to determine the site of deposition of MWCNTs and the type of inflammatory lesions caused by oropharyngeal exposure to MWCNTs. Figure 4A shows that O-MWCNTs delivered by OPA caused centriacinar bronchiolitis/ alveolitis in mice in three of four labs (ML1, ML2, and ML3). One lab (ML4) observed O-MWCNTs primarily within alveolar ducts with little inflammation. In ML4, far fewer O-MWCNTs appeared to be delivered to the lungs (Figure 4A), which correlated with much lower percentages of neutrophils recovered from the mice in that lab (Figure 3A). The inflammatory response associated with MWCNT exposure was characterized by neutrophilia as determined by BALF cell differentials (Figure 4B) and by using immunohistochemical staining with an anti-neutrophil antibody, which revealed neutrophils near terminal bronchioles and in proximity to macrophages containing O-MWCNTs (Figure 4C).


Rats. Ti[O.sub.2]. Neither of the spherical TiO2 nanoparticles--Ti[O.sub.2]-P25 nor Ti[O.sub.2]-A-- caused dose-related changes in the percentage of BALF neutrophils in rats in any of the labs, whereas Ti[O.sub.2]-NBs caused significant neutrophilia in a dose-dependent manner in two of three labs (Figure 5A-C). However, there were visible Ti[O.sub.2] inclusions in macrophages recovered in BALF from exposed rats, indicating that Ti[O.sub.2] nanospheres reached the distal lung after IT. By day 7, all responses had returned to control values. No significant differences were observed between control (DM only) and Ti[O.sub.2]-exposed animals with respect to total protein and LDH assays (data not shown).

MWCNTs. Neutrophils were significantly elevated in rats exposed to the highest dose of all types of MWCNTs (200 [micro]g/rat) compared with controls (DM alone) (Figure 6). All three rat labs (RL1, RL2, and RL3) found a significant dose-dependent effect of the MWCNTs at day 1 postexposure: The percentages of neutrophils were significantly elevated in the 50-[micro]g/rat and 200-[micro]g/rat dose groups compared with controls. Histological evaluation of lung tissue sections demonstrated the presence of inflammatory cells within centriacinar regions similar to that observed in mice (data not shown). Two of three labs also observed a significant effect on neutrophils at the highest dose of O-MWCNTs at 21 days postexposure (data not shown). Although all of the labs found a significant increase in the percentage of neutrophils for the highest dose of P-MWCNTs (200 [micro]g/rat) at 1 day postexposure, the percentage was lower for P-MWCNT than for the same dose of O-MWCNT or F-MWCNT [see Supplemental Material, Figure S2 (]. Two of three labs observed a small but significant effect in the high-dose P-MWCNT group at 21 days postexposure. The percentage of neutrophils in BALF of rats exposed to F-MWCNTs was significantly elevated at the highest dose in all labs at day 1 postexposure, but the neutrophilia was reduced compared with O-MWCNTs at 1 day postexposure and with O-MWCNTs and P-MWCNTs at 21 days postexposure. Interlaboratory precision was high enough to combine results from labs. This permitted a MWCNT toxicity ranking [see Supplemental Material, Figure S2 (], which showed that at the 200-[micro]g dose at 1 day postexposure, O-MWCNTs and F-MWCNTs caused stronger neutrophilic influx than the P-MWCNTs. At 21 days postexposure, there was no significant difference between rats that received DM (control) or the highest dose of F-MWCNTs (see Supplemental Material, Figure S2). However, significant neutrophilia persisted at 21 days postexposure for rats exposed to the highest dose of O-MWCNTs and P-MWCNTs. No significant differences were observed between control and MWCNT-exposed rats with respect to total protein and LDH assays (data not shown). Histopathological examination of the lungs demonstrated acute inflammatory lesions at 1 day postexposure, but no lasting changes were present at 21 days postexposure (data not shown).




The results presented here represent the first attempt by an integrated consortium of independent labs to determine whether the effects of well-characterized ENMs on pulmonary responses in mice and rats could be reliably reproduced by multiple investigators using a harmonized protocol. ENMs presented a challenge for interl aboratory comparisons because of the complexity of variables, including dispersion and characterization. Despite variability between labs in end points such as cell counts and LDH and total protein in BALF, other end points revealed consistent patterns among labs and between rodent models, including neutrophilic inflammation (as a percentage of total cells), and pathologic responses in mice treated with Ti[O.sub.2]-NBs or O-MWCNTs. Because inhalation is a primary route of exposure to particles, the lungs represent a major target organ for the toxicity of ENMs from occupational, accidental, or environmental exposures (Kreyling et al. 2010). In the present study, all of the labs used high bolus doses of ENMs that were delivered by either OPA in mice or IT in rats. This approach was not intended to mimic real-world exposure conditions or deposition patterns in the lung that would occur via inhalation. Instead, we sought to evaluate whether different labs could generate similar and reproducible results with ENMs. Further work should focus on results after inhalation exposure, which is more physiologically relevant, to develop data for risk assessment and characterization to derive exposure standards.



The primary end point that was reliably reproducible in this interlaboratory effort was acute neutrophilia. However, the four mouse labs found different orders of potency for the three types of Ti[O.sub.2] nanoparticles. For example, for day 1, ML1 showed that Ti[O.sub.2]-P25 produced the greatest level of neutrophilia, whereas ML3 showed that Ti[O.sub.2]-NB caused the highest level of neutrophilia. Ti[O.sub.2]-NBs were generally more toxic than Ti[O.sub.2] nanospheres--perhaps because of their shape--and produced neutrophilia in nearly all labs. However, neutrophilia caused by Ti[O.sub.2] nanoparticles did not persist at 7 days post-exposure. Therefore, although acute inflammatory end points may not be the most useful for determining chronic disease such as fibrosis or carcinogenesis, acute inflammation is still the most sensitive end point for toxicity ranking. Future studies comparing spherical to high-aspect-ratio Ti[O.sub.2] should a) address clearance versus retention in the lungs after inhalation, b) evaluate pathologic changes over a period of weeks to months, and c) measure appropriate biomarkers of fibroproliferative and neoplastic disease.

All of the labs observed similar acute inflammatory responses to MWCNTs in mice and rats, as indicated by significant neutrophilic influx into the lungs of exposed animals and similar lung pathology. Three of four mouse labs found O-MWCNTs to be the most inflammatory, as indicated by neutrophil influx at 1 day postexposure, whereas F-MWCNTs were the least pro inflammatory. All three rat labs also observed that O-MWCNTs were the most inflammatory [see Supplemental Material, Figure S2 (http://]. This judgment about relative toxicological potency is based on the consistent findings of an onset of inflammation at a lower dose (i.e., 50 [micro]g IT) combined with persistence of neutrophilia at 21 days postexposure. Therefore, both mice and rats used in the consortium effort independently identified O-MWCNTs as having the greatest proinflammatory effect, suggesting that residual catalytic metals [see Xia et al. (2013) for physicochemical characterization] may have contributed to the inflammatory response. Moreover, the mouse and rat working groups observed similar pathology in animals exposed to O-MWCNTs.

In retrospect, we can identify aspects of the study design that worked well and those that could be considered for improvement in future interlaboratory in vivo comparison studies with ENMs. The concordance in findings in terms of neutrophilia and histopathol ogical changes that were detected with the Ti[O.sub.2]-NBs and MWCNTs confirms the importance of careful planning and lends strength to conclusions made about the relative acute potency of these materials. However, the variability found in the absolute number of neutrophils highlights some methodological differences that were not considered at the outset of the studies. Even though by design the rat and mouse groups used similar dispersion protocols to break up large agglomerates, it was beyond the scope of this project to ensure that all users had identical dispersion instrumentation. Thus, it was not technically possible to ensure that all labs delivered ENMs that were identical in particle size distribution. Approaches that have been recently described (Taurozzi et al. 2011, 2013) could be considered for future efforts, but they were not available at the time the studies were conducted.

Other design problems to overcome include differences in instillation/aspiration and lavage techniques from one lab to another. Despite detailed planning, it was not realistic to mandate identical techniques across the labs because that would have involved significant expenditure of animals and time for training. It may not be possible to overcome these problems; thus, careful consideration should be given to the end points that can be reliably used for comparisons. Last, inherently low-toxicity ENMs such as Ti[O.sub.2] are perhaps not as useful for interl aboratory comparisons as more potent materials. More specifically, the spherical Ti[O.sub.2] particles were not potent enough in these bioassays to be identified consistently across the labs as having acute in vivo toxicity upon bolus delivery. In contrast, the MWCNTs were sufficiently potent to be identified as potentially hazardous by all labs in this round-robin effort (i.e., sufficiently insensitive to the methodological differences among the labs).

It is important to note that pathology might be affected by nanoparticle delivery modes. The fibrotic response to MWCNTs in mice has been reported to be more diffuse in inhalation exposures compared with aspiration exposure (Shvedova et al. 2008). The issue of MWCNT dispersion (i.e., agglomeration state) and consequent disease is a critical one in assessing health risks. For example, inhalation of agglomerated MWCNTs causes a different pathology (less interstitial fibrosis) than dispersed fibrillar structures (Ma-Hock et al. 2009; Pauluhn 2010). Other recent studies (Porter et al. 2010; Wang et al. 2011) reported that OPA aspiration of well-dispersed MWCNTs caused more fibrosis and growth-factor production than did non dispersed MWCNTs. All of the labs in the consortium used the same dispersion medium for suspending MWCNTs or Ti[O.sub.2] nanoparticles. Nevertheless, it was apparent that some agglomeration occurred, particularly for MWCNTs. Future studies should carefully evaluate whether functionalization of MWCNTs or other ENMs influences agglomeration status and surface properties, which could in turn alter pathologic responses resulting from bolus delivery of particles to the lungs in a liquid suspension. Responses following more realistic and physiological inhalation exposures should be evaluated with these materials to confirm the hazard ranking and to derive the lowest or no-effect levels for purposes of risk characterization, although that was not the purpose of the experiments presented here.

MWCNTs and Ti[O.sub.2]-NBs represent ENMs that are referred to as high-aspect-ratio nanoparticles (i.e., fiber-like structures that have nanoscale width but can be micrometers in length). A principal characteristic of high-aspect-ratio nanoparticles that is shared by pathogenic fibers, such as asbestos, is impeded clearance from the lungs after inhalation exposure, which may lead to the pathogenesis of diseases such as pulmonary fibrosis and mesothelioma (Bonner 2010). There is evidence that high-aspect-ratio Ti[O.sub.2]-NBs and long MWCNTs are more pathogenic and may elicit "frustrated phagocytosis" by macrophages, lysosomal disruption, and impaired clearance (Donaldson et al. 2011; Hamilton et al. 2009). Therefore, exposure to some of the ENMs used in this consortium study might be cause for concern about human health.

Pulmonary toxicology studies in rodents have shown that OPA or IT exposure to MWCNTs at high doses/concentrations results in lung inflammation and interstitial pulmonary fibrosis, similar to that of exposure to asbestos fibers (Han et al. 2010; Mercer et al. 2011; Porter et al. 2010; Ryman-Rasmussen et al. 2009a; Wang et al. 2011). Inhaled MWCNTs can also cause inflammatory reactions by migrating to the pleural membrane surrounding the lungs (Porter et al. 2010; Ryman-Rasmussen et al 2009b). Direct intraperitoneal injection of very high doses of other MWCNTs have also been reported to induce mesothelioma in genetically susceptible mice that lack an allele of the tumor suppressor p53 (Takagi et al. 2008). Some caution should be taken in interpreting these latter results, because p53-deficient mice spontaneously develop tumors. In addition, a 2-year study showed that MWCNTs possessed no carcinogenicity when injected into the peritoneal cavity of male Wistar rats (Muller et al. 2009), although that study used very short MWCNTs (< 1 [micro]n). However, the injection studies mentioned above did not address direct exposure to the lungs. It should also be stressed that it is unclear to what extent the differences in MWCNT properties (i.e., associated metal content, dispersion state/method, aspect ratio, rigidity) and means of exposure played a role in disparate outcomes. Therefore, it remains to be determined whether MWCNTs are carcinogenic in inhalation studies.

Thus far, no human disease has been linked to exposure to carbon nanotubes. Therefore, the scientific community has a unique opportunity to address human health effects in a preventive manner and reduce potential adverse health effects by establishing assays to predict disease outcome using in vitro and in vivo models. This article on interlaboratory studies in rodents exposed to ENMs and the accompanying article on interlaboratory in vitro studies (Xia et al. 2013) comprise one of the first attempts to assess the reproducibility of experiments among different labs using harmonized experimental protocols and identical ENMs.

Outlook and Future Directions

As part of the nanotechnology revolution, a vast array of industrial and consumer products is emerging on the market. Many nanomaterials are already in the marketplace in consumer products [a comprehensive list is maintained and updated by the Project on Emerging Technologies (2013)]. It is not feasible or practical to test all of these ENMs using in vivo rodent models. Therefore, predictive high throughput screening of materials using validated in vitro model systems, along with with more thorough analyses of selected ENMs using realistic in vivo rodent models and realistic exposures, will likely be the only practical way to determine the toxic potential of an enormous variety of emerging nanomaterials (Nel et al. 2009). Standard protocols should be used for in vitro screening and the resulting data made publicly available through a centralized database. In addition, a centralized repository for ENMs should be established to provide well-characterized ENMs in large quantities to investigators.

We are only beginning to understand the mechanisms of toxicity of the increasing variety of emerging ENMs. Growing evidence indicates that nanosizing particles increases toxicity because of a proportional increase in surface area that is then available to generate reactive oxygen species (ROS), primary factors that drive cellular stress and disease pathogenesis (Nel et al. 2006). However, in addition to the obvious role of increased surface area and ROS generation, nanosized particles could be capable of moving across cellular barriers to interact with subcellular structures (e.g., mitochondria, microtubules, organelles, DNA) in potentially unique ways that we do not yet fully comprehend. There is also evidence that ENMs traverse the pulmonary epithelial--endothelial barrier to gain access to secondary target tissues (Aiso et al. 2011; Kreyling et al. 2002, 2009). Alternatively, ENMs could influence immune responses of secondary target tissues by stimulating the release of lung cytokines into the systemic circulation (Mitchell et al. 2007). Therefore, to keep pace with the emerging nanotechnology industry and associated human and environmental exposures, more research is required to elucidate common mechanisms of nanoparticle-induced adverse health effects.

Unfortunately, the amount of funding for nanotoxicology research on health effects lags far behind what is available for nanotechnology research and development. The disproportionate emphasis on nanotechnology research and development compared with issues of risk for human health and the environment could result in a new wave of occupational and environmental health crises. Although many ENMs will present little or no risk, it is inevitable that at least some ENMs will pose a significant risk to human health and the environment. Our consortium experiments described here are significant in providing results of a coordinated effort toward addressing hazard identification of highpriority ENMs. Future research should expand this consortium effort to allow for toxicity testing and exposure assessment to ensure the safe continuation and economic viability of nanotechnology.

Caption: Figure 1. Stimulation of neutrophilic inflammation in the lungs of C57BL/6 mice by Ti[O.sub.2]-P25 (A), Ti[O.sub.2]-A (B), or Ti[O.sub.2]-NB (C) evaluated in four labs (ML1, ML2, ML3, and ML4). Values are the mean [+ or -] SE percentage of neutrophils in BALF 1 day after exposure to DM only (control) or Ti[O.sub.2] ENMs at 40 [micro]g/50 [micro]L.

* p < 0.05, ** p < 0.01, and # p < 0.001 compared with controls.

Caption: Figure 2. Photomicrographs of H&E-stained lung tissue 1 day after exposure of C57BL/6 mice to DM alone (control; A, D, G, J) or Ti[O.sub.2]-NB at 40 [micro]g/50 [micro]L DM (B, C, E, F, H, I, K, L). Photomicrographs are representative sections from each of the four labs: (A-C ML1, (D-F) ML2, (G-I) ML3, and (J-L) ML4. (A, D, G, J, B, E, H, K Bright-field light microscopy of representative sections of lung from control mice (A, D, G, J) and Ti[O.sub.2]-NB-exposed mice (B, E, H, K); sections from Ti[O.sub.2]-NB-exposed mice show inflammatory lesions primarily localized to alveolar duct bifurcations. (C, F, I, L) Polarized light microscopy of the same images shown in B, E, H, and K show inflammation at an alveolar duct bifurcation. Abbreviations: a, alveolus; ad, alveolar ducts; bv, blood vessel; e, airway epithelium; tb, terminal bronchioles. Arrows indicate Ti[O.sub.2]-NBs within macrophages at alveolar duct bifurcations, and asterisks (*) indicate inflammatory foci. All photomicrographs were taken at the same magnification; bar = 50 [micro]m.

Caption: Figure 3. Stimulation of neutrophilic inflammation in the lungs of mice by O-MWCNT (A), P-MWCNT (B), or F-MWCNT (C) evaluated in four labs (ML1, ML2, ML3, ML4). Values shown are the mean [+ or -] SE percentage of neutrophils in BALF 1 day after exposure to DM only (control) or MWCNTs at 40 [micro]g/50 [micro]L. (A) Significant increase induced by O-MWCNT in all four labs. (B) Significant increase induced by P-MWCNT in two labs. (C) Significant increase induced by F-MWCNT in three labs, F-MWCNT albeit to a lesser extent than that induced by O-MWCNT.

* p < 0.05, ** p < 0.01, and # p < 0.001 compared with controls.

Caption: Figure 4. Results of lung histopathology (A), BAL cytospins (B), and immunohistochemistry (C) for mice exposed to DM only (control) or O-MWCNTs (40 [micro]g/50 [micro]L). Abbreviations: a, alveolus; AD, alveolar ducts; BV, blood vessel; TB, terminal bronchioles. (A) Histopathology showing lung inflammatory response to O-MWCNTs. Centriacinar bronchiolitis/alveolitis (dashed arrows) was induced by O-MWCNTs in three of four labs (ML1, ML2, ML3); one lab (ML4) found some deposition of O-MWCNTs in alveolar ducts with marginal inflammation. Solid arrows indicate macrophages containing O-MWCNT. (B) BAL cytospin images of cells from the lungs of mice exposed to DM (control) or O-MWCNTs; > 95% of macrophages from O-MWCNT-exposed animals were enlarged, activated alveolar macrophages with numerous MWCNT inclusions (solid arrows) and neutrophils that do not contain MWCNTs (dashed arrows). The images are from a single lab (ML3) but are typical of responses from ML1 and ML2. (C) Immunohistochemistry using a monoclonal rat anti-mouse neutrophil (allotypic marker clone 7/4) antibody showing the location of neutrophils (dashed arrows) near terminal bronchioles and in relation to macrophages containing O-MWCNT (solid arrows). Representative images are from ML3.

Caption: Figure 5. Stimulation of neutrophilic inflammation in the lungs of rats by Ti[O.sub.2]-P25 (A), Ti[O.sub.2]-A (B), or Ti[O.sub.2]-NB (C) evaluated in three labs (RL1, RL2, and RL3). Values are the mean [+ or -] SE percentage of neutrophils in BALF 1 day after exposure to DM only (control) or Ti[O.sub.2] ENMs (20, 70, or 200 [micro]g/250 [micro]L).

* p < 0.05 compared with controls.

Caption: Figure 6. Stimulation of neutrophilic inflammation in the lungs of rats by O-MWCNT (A), P-MWCNT (B), or F-MWCNT (C) evaluated in three labs (RL1, RL2, and RL3). Values are the mean [+ or -] SE percentage of neutrophils in BALF of rats 1 day after treatment with DM only (control) or MWCNTs (10, 50, or 200 [micro]g/250 [micro]L).

* p < 0.05 compared with controls.


Aiso S, Kubota H, Umeda Y, Kasai T, Takaya M, Yamazaki K, et al. 2011. Translocation of intratracheally instilled multiwall carbon nanotubes to lung-associated lymph nodes in rats. Ind Health 49(2):215-220.

Bonner JC. 2010. Nanoparticles as a potential cause of pleural and interstitial lung disease. Proc Am Thorac Soc 7(2):138-141.

Borm PJ, Robbins D, Haubold S, Kuhlbusch T, Fissan H, Donaldson K, et al. 2006. The potential risks of nanomaterials: a review carried out for ECETOC. Part Fibre Toxicol 3:11; doi:10.1186/1743-8977-3-11 [Online 14 August 2006].

Card JW, Zeldin DC, Bonner JC, Nestmann ER. 2008. Pulmonary applications and toxicity of engineered nanoparticles. Am J Physiol 295(3):L400-L411.

Donaldson K, Murphy F, Schinwald A, Duffin R, Poland CA. 2011. Identifying the pulmonary hazard of high aspect ratio nanoparticles to enable their safety-by-design. Nanomedicine (Lond) 6(1):143-156.

Hamilton RF, Wu N, Porter D, Buford M, Wolfarth M, Holian A. 2009. Particle length-dependent titanium dioxide nanomaterials toxicity and bioactivity. Part Fibre Toxicol 6:35; doi:10.1186/1743-8977-6-35 [Online 31 December 2009].

Han SG, Andrews R, Gairola CG. 2010. Acute pulmonary response of mice to multi-wall carbon nanotubes. Inhal Toxicol 22(4):340-347.

Kreyling WG, Hirn S, Schleh C. 2010. Nanoparticles in the lung. Nat Biotechnol 28(12):1275-1276.

Kreyling WG, Semmler M, Erbe F, Mayer P, Takenaka S, Oberdorster G, et al. 2002. Minute translocation of inhaled ultrafine insoluble iridium particles from lung epithelium to extrapulmonary tissues. Ann Occup Hyg 46(suppl 1):223-226.

Kreyling WG, Semmler-Behnke M, Seitz J, Scymczak W, Wenk A, Mayer P, et al. 2009. Size dependence of the translocation of inhaled iridium and carbon nanoparticle aggregates from the lungs of rats to the blood and secondary target organs. Inhal Toxicol 21(suppl 1):55-60.

Ma-Hock L, Treumann S, Strauss V, Brill S, Luizi F, Mertler M, et al. 2009. Inhalation toxicity of multiwall carbon nanotubes in rats exposed for 3 months. Toxicol Sci 112(2):468-481.

Mercer RR, Hubbs AF, Scabilloni JF, Wang LY, Battelli LA, Friend S, et al. 2011. Pulmonary fibrotic response to aspiration of multi-walled carbon nanotubes. Part Fibre Toxicol 8:21; doi:10.1186/1743-8977-8-21 [Online 22 July 2011].

Mitchell LA, Gao J, Wal RV, Gigliotti A, Burchiel SW, McDonald JD. 2007. Pulmonary and systemic immune response to inhaled multiwalled carbon nanotubes. Toxicol Sci 100(1):203-214.

Muller J, Delos M, Panin N, Rabolli V, Huaux F, Lison D. 2009. Absence of carcinogenic response to multiwall carbon nanotubes in a 2-year bioassay in the peritoneal cavity of the rat. Toxicol Sci 110(2):442-448.

Nel AE, Madler L, Velegol D, Xia T, Hoek EM, Somasundaran P et al. 2009. Understanding biophysicochemical interactions at the nano-bio interface. Nat Mater 8(7):543-557.

Nel A, Xia T, Madler L, Li N. 2006. Toxic potential of materials at the nanolevel. Science 311:622-627.

Oberdorster G, Oberdorster E, Oberdorster J. 2005. Nanotoxicology: an emerging discipline evolving from studies of ultrafine particles. Environ Health Perspect 113:823-839.

Pauluhn J. 2010. Subchronic 13-week inhalation exposure of rats to multiwalled carbon nanotubes: toxic effects are determined by density of agglomerate structures, not fibrillar structures. Toxicol Sci 113(1):226-242.

Porter D, Sriram K, Wolfarth M, Jefferson A, Schwegler-Berry D, Andrew M, et al. 2008. A biocompatible medium for nanoparticle dispersion. Nanotoxicology 2(3):144-154.

Porter DW, Hubbs AF, Mercer RR, Wu N, Wolfarth MG, Sriram K, et al. 2010. Mouse pulmonary dose- and time course-responses induced by exposure to multi-walled carbon nanotubes. Toxicology 269(2-3):136-147.

Project on Emerging Nanotechnologies. 2013. Consumer Products: An Inventory of Nanotechnology-Based Consumer Products Currently on the Market. Available: [accessed 30 April 2013].

Robichaud CO, Uyar AE, Darby MR, Zucker LG, Wiesner MR. 2009. Estimates of upper bounds and trends in nano-Ti[O.sub.2] production as a basis for exposure assessment. Environ Sci Technol 43:4227-4233.

Ryman-Rasmussen JP, Cesta MF, Brody AR, Shipley-Phillips JK, Everitt J, Tewksbury EW, et al. 2009a. Inhaled carbon nanotubes reach the subpleural tissue in mice. Nat Nanotechnol 4(11):747-751.

Ryman-Rasmussen JP, Tewksbury EW, Moss OR, Cesta MF, Wong BA, Bonner JC. 2009b. Inhaled multi-walled carbon nanotubes potentiate airway fibrosis in murine allergic asthma. Am J Respir Cell Mol Biol 40(3):349-358.

Shvedova AA, Kisin E, Murray AR, Johnson VJ, Gorelik O, Arepalli S, et al. 2008. Inhalation vs. aspiration of single-walled carbon nanotubes in C57BL/6 mice: inflammation, fibrosis, oxidative stress, and mutagenesis. Am J Physiol Lung Cell Mol Physiol 295(4):L552-L565.

Takagi A, Hirose A, Nishimura T, Fukumori N, Ogata A, Ohashi N, et al. 2008. Induction of mesothelioma in p53+/mouse by intraperitoneal application of multi-wall carbon nanotube. J Toxicol Sci 33(1):105-116.

Taurozzi JS, Hackley VA, Wiesner MR. 2011. Ultrasonic dispersion of nanoparticles for environmental, health, and safety assessment--issues and recommendations. Nanotoxicology 5(4):711-729.

Taurozzi JS, Hackley VA, Wiesner MR. 2013. A standardized approach for the dispersion of titanium dioxide nanoparticles in biological media. Nanotoxicology 7(4):389-401; doi:10.3109/17435390.2012.665506 [Online 20 March 2012].

Wang X, Xia T, Ntim SA, Ji Z, Lin S, Meng H, et al. 2011. Dispersal state of multiwalled carbon nanotubes elicits profibrogenic cellular responses that correlate with fibrogenesis biomarkers and fibrosis in the murine lung. ACS Nano 5(12):9772-9787.

Xia T, Hamilton RF Jr, Bonner JC, Crandall ED, Elder A, Fazlollahi F, et al. 2013. Interlaboratory evaluation of in vitro cytotoxicity and inflammatory responses to engineered nanomaterials: the NIEHS Nano GO Consortium. Environ Health Perspect 121:683-690.

Xia T, Li N, Nel AE. 2009. Potential health impact of nanoparticles. Annu Rev Public Health 30:137-150.

James C. Bonner, (1) Rona M. Silva, (2) Alexia J. Taylor, (1) Jared M. Brown, (3) Susana C. Hilderbrand, (3) Vincent Castranova, (4) Dale Porter, (4) Alison Elder, (5) Gunter Oberdorster, (5) Jack R. Harkema, (6) Lori A. Bramble, (6) Terrance J. Kavanagh, (7) Dianne Botta, (7) Andre Nel, (8) and Kent E. Pinkerton (2)

(1) Department of Environmental and Molecular Toxicology, North Carolina State University, Raleigh, North Carolina, USA; (2) Department of Anatomy, Physiology, and Cell Biology, School of Veterinary Medicine, University of California, Davis, Davis, California, USA; (3) Department of Pharmacology and Toxicology, Brody School of Medicine, East Carolina University, Greenville, North Carolina, USA; (4) Health Effects Laboratory, National Institute for Occupational Safety and Health, Morgantown, West Virginia, USA; (5) Department of Environmental Medicine, University of Rochester, Rochester, New York; (6) Department of Pathobiology and Diagnostic Investigation, Michigan State University, East Lansing, Michigan, USA; (7) Department of Environmental and Occupational Health Sciences, University of Washington, Seattle, Washington, USA; (8) Center for Environmental Implications of Nanotechnology, California Nanosystems Institute, Los Angeles, California, USA

Address correspondence to J.C. Bonner, Department of Environmental and Molecular Toxicology, North Carolina State University, Raleigh, NC 27606 USA. Telephone: (919) 515-8615. E-mail:; or K.E. Pinkerton, Department of Anatomy, Physiology, and Cell Biology, School of Veterinary Medicine, University of California Davis, Davis, CA 95616 USA. Telephone: (530) 752-8334. E-mail:

Supplemental Material is available online (http://

We thank S. Smiley-Jewell, L. Franzi, and C. TeeSy (University of California, Davis) for technical editing of the manuscript; B. Baisch, N. Corson, P. Mercer, and A. Walker (University of Rochester), and C. Weldy, C. White, and S. Schmuck (University of Washington) for excellent technical assistance; and D. Telesca (University of California, Los Angeles) for helpful discussions regarding approaches for statistical analysis. We thank S. Nadadur, [National Institute of Environmental Health Sciences (NIEHS), Division of Extramural Research and Training] for initiation and direction of these consortium efforts. We also thank T. Schug (NIEHS) for administrative organization and planning of consortium conferences.

This work was funded by NIEHS grants RC2 ES018772 (J.C.B.), RO1 ES019311 (J.M.B.), RC2 ES018741 (A.E. and G.O.), RC2ES197756 (J.R.H.), R01 ES016189 (T.J.K.), P30 ES007033 (T.J.K.), RC2 ES018766 (A.N.), and RC1 S018232 (K.E.P.).

The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the National Institute for Occupational Safety and Health.

The authors declare they have no actual or potential competing financial interests.

Received 29 June 2012; accepted 1 April 2013.
COPYRIGHT 2013 National Institute of Environmental Health Sciences
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2013 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Research
Author:Bonner, James C.; Silva, Rona M.; Taylor, Alexia J.; Brown, Jared M.; Hilderbrand, Susana C.; Castra
Publication:Environmental Health Perspectives
Article Type:Report
Geographic Code:1USA
Date:Jun 1, 2013
Previous Article:Residential proximity to Methyl bromide use and birth outcomes in an agricultural population in California.
Next Article:Bisphenol a exposure during adulthood causes augmentation of follicular atresia and luteal regression by decreasing 17[beta]-Estradiol synthesis via...

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters